Journal of Vaccines & Vaccination

In situ immunization followed by adoptive cellular therapy against breast cancer

International Conference & Exhibition on Vaccines & Vaccination

22-24 Nov 2011 Philadelphia Airport Marriott, USA

Masoud H Manjili

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

Attempts to cure breast cancer by means of vaccination or adoptive cellular therapy (ACT) have not been successful. Th is is primarily due to the presence of tumor-induced immune suppressive mechanisms as well as the failure of tumor-reactive T cells to provide long-term memory responses in vivo. In order to address these clinically important challenges we developed an ex vivo protocol for the expansion of tumor-sensitized immune cells obtained from tumor- bearing animals prior to or aft er local radiation therapy. We used an antigen-free protocol which included bryostatin 1/ionomycin (B/I) and sequential common gamma-chain cytokines (IL-7/ IL-15 + IL-2). Th e proposed protocol expanded tumor-reactive T cells as well as the activated non-T cells including NK T cell s, NK cells and IFN-γ producing killer dendritic cells (IKDC). Anti-tumor effi cacy of T cells depended on the presence of non-T cells. Th e eff ector non-T cells also rendered T cells resistant to myeloid-der ived suppressor cells (MDSC). Radiation therapy altered phenotypic distribution and diff erentiation of T cells, as well as their ability to generate central memory T cells (TCM). ACT by means of the expanded cells, protected animals from tumor challenge and generated long-term memory responses against the tumor, provided that leukocytes were derived from tumor-bearing animals prior to radiation therapy. Th e ex vivo protocol was also able to expand HER-2/neu-specifi c T cells derived from PBMC of patients with breast carcinoma. Th ese data suggest clinical applicability of the proposed ACT protocol in breast cancer patients.

Biography :

Dr. Masoud H Manjili has completed his DVM at the age of 28 from the University of Tehran, his Ph.D in immunology at the age of 33 years from the University of Sydney, Australia and postdoctoral studies in tumor immunology from Roswell Park Cancer Institute, Buffalo New York. He is an Assistant Professor of Immunology. He has published more than 40 papers in reputed journals and three book chapters. He is serving as a managing editor of Frontiers in Bioscience and an editorial board member of the Journal of Clinical & Cellular Immunology